Repurposing Anticancer Drugs in Parkinson's Treatment: Molecular Pathways Driving Neuroprotection and Therapeutic Advancement. (PubMed, Mol Neurobiol) - Sep 17, 2026 - "Ixazomib enhances α-synuclein clearance via autophagy in preclinical models. Nilotinib showed poor CNS penetration (< 0.3% in CSF), resulting in worsening motor outcomes. Relatlimab, trehalose, and lapatinib demonstrated preclinical benefits through inhibition of α-synuclein spread, mTOR-independent autophagy, and multi-pathway neuroprotection, respectively. The AZA-PD Phase 2 trial (azathioprine) demonstrated a favourable safety and tolerability profile and offered valuable insights into peripheral immune modulation in early PD, though it did not meet its primary endpoint of slowing disease progression...Mechanistic convergence provides a rationale for repurposing drugs; however, clinical success requires addressing the unique challenges of neurodegeneration. Future approaches should focus on precision medicine, innovative delivery systems, and multi-target interventions rather than direct therapeutic translation."
Journal • Review • CNS Disorders • Immune Modulation • Immunology • Metabolic Disorders • Movement Disorders • Oncology • Parkinson's Disease • Targeted Protein Degradation
|
|
Shivakumar; Bharathi Doddla Raghunathanaidu; Poonam Laxman Bedage; Purnima Chettri; Syed Sagheer Ahmed; Yarava Dhanush
|